Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DaxibotulinumtoxinA for Upper Limb Spasticity
NCT03821402Phase 2Completed
- Sponsor
- Revance Therapeutics
- Start
- Dec 2018
- Primary completion
- Nov 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of daxibotulinumtoxinA in Upper limb spasticity (4 arms), sponsored by Revance Therapeutics. Primary endpoints: Modified Ashworth Scale in the Suprahypertonic Muscle Group at Week 6 and Physician Global Impression of Change at Week 6. Started Dec 2018; status: completed.
02
Drugs
daxibotulinumtoxinA
03
Conditions
Upper limb spasticity
Beyond the preview
Go deeper on NCT03821402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03821402.